503 results about "Small intestine" patented technology

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The invention relates to the field of biological agents, in particular to a compound probiotic preparation rich in organic selenium and a preparation method of the compound probiotic preparation, and efficient synergistic delivery is achieved through plant micromolecule organic selenium extraction and a multi-layer microemulsion embedding technology. The preparation consists of a core active component, a carrier system and a curcumin compound. The plant micromolecular organic selenium is extracted from cardamine hupingshanesis and high-selenium corn flour through an HLUP technology, and the bioavailability is remarkably improved. A corn protein modified W / O / W microemulsion is adopted as a carrier, an outer layer membrane is stable in an acid environment, and an inner layer accurately releases selenium to small intestines; a protective agent composed of trehalose and glucose inhibits ice crystal damage, and glutaraldehyde crosslinking enhances the mechanical strength of the membrane. Curcumin and selenium synergistically enhance antioxidant and immunomodulatory functions, and promote phagocytic activity of macrophages. The stability and bioavailability bottlenecks of a traditional preparation are broken through, and an innovative scheme is provided for functional food development.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

The invention provides a preparation method of a calcium emulsifying and embedding system with high bioaccessibility, which comprises the following steps: S1) heating and mixing biomacromolecules and an emulsifier in water to obtain a water phase; the biomacromolecules are protein colloids and / or polysaccharide colloids; the method comprises the following steps: heating and mixing a calcium source substance and anhydrous cream to obtain an oil-solid phase; and S2) mixing the oil-solid phase with a water phase, and emulsifying to obtain the calcium emulsifying and embedding system. Compared with the prior art, the preparation method has the advantages that the natural macromolecular protein and / or polysaccharide with high nutritional value is used as a carrier, the calcium source substance is embedded through a water-oil-solid three-phase emulsification technology, and the preparation method is simple, easy to operate, low in cost and environmentally friendly; in addition, a water-oil-solid three-phase homogenized emulsion is created, the problem that the dispersion stability of milk mineral salt in a liquid food matrix is poor is effectively solved, release of free calcium ions in the small intestine environment can be promoted, and the calcium bioaccessibility is remarkably improved.

The invention belongs to the technical field of feed additives, and particularly relates to slow-release fat powder for pigs and a preparation method of the slow-release fat powder. The slow-release fat powder for pigs comprises an intragastric adhesion-slow release layer, a small intestine forepart bile acid response controlled release layer and a small intestine posterior microbe response controlled release layer. The prepared slow-release fat powder for the pigs is good in stability, accurate release of different nutritional ingredients in different parts of gastrointestinal tracts of the pigs can be achieved, and powerful support is provided for sustainable development of the pig raising industry.

Methods of enhancing visualization of a body lumen. A device including a capsule endoscope and a plurality of struts attached thereto may be positioned into the body lumen. The plurality of struts of the device may self-expand within the body lumen from a constrained configuration to an expanded configuration in which the plurality of struts extend both radially and axially away from a camera lens of the capsule endoscope so as to form a frame around the camera lens in the expanded configuration. The camera lens may image through the frame into the body lumen. At least a portion of the frame or a material constraining the struts of the frame may dissolve to allow passage of the device from the body lumen.

The invention relates to the field of microorganisms, and discloses a Lactococcus lactis subsp. Lactis VB346 which is preserved in the China Center for Type Culture Collection on September 20, 2024, and the preservation number is CCTCC NO: M 20242013. The invention further discloses a preparation method of the Lactococcus lactis subsp. Lactis VB346. The lactococcus lactis subsp. Lactis VB346 disclosed by the invention has the capability of efficiently degrading purine nucleoside, and can decompose purine nucleoside in ingested food in intestinal tracts, so that the absorption amount of purine nucleoside by small intestines is reduced. The polypeptide has the ability of degrading bilirubin, and can be used for treating or improving hyperbilirubinemia, or improving liver and gall injury caused by hyperbilirubin; meanwhile, the acid resistance required by survival in the stomach, the cholate tolerance required by survival in the intestinal tract and the stable survival ability in the intestinal tract are achieved, and the bacillus subtilis has huge application prospects in preparation of drugs, microbial agents, health care products or food.

The invention belongs to the field of food processing, and discloses a preparation method and application of a targeted colon delivery polyunsaturated fatty acid grease microcapsule. 11S globulin in soybeans and Arabic gum are used as wall materials of the microcapsule, complex coacervation of the 11S globulin in the soybeans and the Arabic gum is induced under a certain pH condition, so that oil drops are wetted by a coacervate, a core-shell structure is formed, a coacervate phase is further stabilized through glucan to inhibit coalescence, and on the basis, the microcapsule is prepared. And tannic acid, polysaccharide and protein can form hydrogen bonds and generate hydrophobic interaction to further crosslink the condensed phase to obtain the microcapsule capable of resisting digestion of the stomach and the small intestine, so that colon delivery of polyunsaturated fatty acid is realized.

The invention discloses a capsule medicament for endoscopic treatment of ulcerative colitis and a preparation method thereof, and belongs to the technical field of biological medicine, the capsule medicament is composed of a capsule matrix and a drug matrix; by adopting a dual control mechanism of an enteric layer coating and a pH response layer coating, accurate release of a medicine at a colon diseased region is ensured, medicine waste of the stomach and the small intestine is reduced, the medicine concentration at a focus is improved, mesalazine or budesonide is combined with the composite composition for treatment, inflammatory response is rapidly inhibited, acute symptoms are controlled, and the curative effect is good. A multi-mechanism synergistic treatment mode is adopted, the anti-inflammatory and repairing effects are enhanced, the clinical remission rate and the mucous membrane healing rate are remarkably improved, the pH response layer is dissolved in a colon alkaline environment, and the MMP-9 peptide cross-linking agent is subjected to enzymolysis at an inflammation part, so that the medicine is continuously released at a focus, the administration frequency is reduced, the compliance of a patient is improved, and the curative effect is good. In addition, the spherical gel particles in the medicament can prevent the medicament from being disintegrated too early in the intestinal tract, and the long-acting effect can be maintained.

The invention relates to the technical field of feed additives, and discloses a ruminant animal fattening and growth-promoting feed additive which comprises the following components in percentage by mass: 22-28 parts of phytosterol, 42-48 parts of a rumen protection type amino acid compound, 11-14 parts of a compound probiotic preparation, 6-7.5 parts of a compound enzyme preparation, 9-11 parts of a trace element compound and 4-4.8 parts of a buffer system. According to the preparation method of the fattening and growth-promoting feed additive for ruminant animals, a modified hydrogenated palm oil and lecithin compound is used as a rumen protection type amino acid coating material, and a high-pressure homogenizer is used for performing multi-stage homogenizing treatment, so that a coating layer is more compact in structure, and the weight of the coating layer is increased; the rumen microorganism lipase decomposition resistance is enhanced through the synergistic effect of the composite material, particle distribution is optimized in combination with a refined homogenizing process, the release controllability and absorption efficiency of amino acid in small intestines are improved, and the problems that a traditional single coating material is easy to decompose and the particle size is extensively controlled are solved.

The invention relates to a lactobacillus rhamnosus YYSJ019 strain for relieving obesity and application of the lactobacillus rhamnosus YYSJ019 strain. The lactobacillus rhamnosus YYSJ019 strain is classified and named as lactobacillus rhamnosus, and the preservation number of the lactobacillus rhamnosus YYSJ019 strain is CGMCC (China General Microbiological Culture Collection Center) No.33472. The strain has good tolerance and high surface hydrophobicity in gastric juice, and has the potential of smoothly entering the gastrointestinal tract of a human body; the bacterial strain has excellent intestinal adhesion capability, and provides a basis for continuously playing a probiotic effect; the strain can slow down weight gain of obese mice and improve fat accumulation, liver injury and inflammation in bodies of the obese mice; the blood sugar metabolism capability and the blood fat metabolism capability can also be improved, and the potential of preventing and treating hyperglycemia or hyperlipidemia is achieved; in addition, a mouse small intestine endocrine cell line (STC-1 cell line) can be stimulated to generate the glucagon-like peptide-1, and the glucagon-like peptide-1 has the potential of improving diseases caused by insufficient secretion of the glucagon-like peptide-1; the effects of reducing uric acid in vitro and reducing uric acid in vivo are achieved, and the potential of preventing and treating hyperuricemia is achieved.

The invention belongs to the technical field of medicines, and particularly provides a solid dispersion as well as a preparation method and application thereof. The solid dispersion comprises a carrier material, and further comprises quercetagetin and phospholipid, the mass ratio of the quercetagetin to the phospholipid is 1: (0.3-1.5), and the carrier material comprises one or more of a hydrophilic polymer and a pH-dependent polymer. Wherein the quercetagetin and the phospholipid are combined through an intermolecular force, so that the quercetagetin obtains a lipid material similar to a cell membrane structure, a cell membrane bionic phospholipid compound is formed, the cell membrane bionic phospholipid compound can be naturally compatible with an upper wall cell membrane of a small intestine, and the permeation transmembrane capability of the quercetagetin is better promoted; the quercetagetin is added into the solid dispersion, so that more quercetagetin can enter systemic circulation and lymphatic circulation, and therefore, the solid dispersion can strengthen transmembrane absorption while strengthening dissolution, so that the solid dispersion has high bioavailability.

The invention discloses a preparation method of immunoglobulin composite liposome nanoparticles with a controlled release characteristic, and belongs to the field of food nutrition and functional factors. Cholesterol and sitosterol are creatively used as auxiliary supports of a lecithin liposome skeleton, the stability of an immunoglobulin liposome nanoparticle structure is improved, the slow release property in the simulation effect process is improved, and a pH response type hydrogel film formed based on electrostatic crosslinking is prepared from calcium alginate and chitosan. A more stable double-layer shell-core structure is formed, so that the stability of embedded immune globulin molecules in gastric juice is further improved, and fixed-point slow release in small intestines is realized.

The invention relates to composite hydrogel for tissue repair as well as a preparation method and application of the composite hydrogel. The composite hydrogel is prepared from a methacrylated acellular matrix, nano clay (LAP), a photoinitiator, carboxymethyl chitosan (CMCS) and water. The acellular matrix is modified through methylacryloylation, and a polymer network is reinforced by combining nano-clay, so that the mechanical strength is improved; and carboxymethyl chitosan adjusts the degradation rate, constructs a pore structure and endows antibacterial and anti-inflammatory functions. The preparation method comprises the following steps: dissolving the methacrylated acellular matrix in the PBS containing the photoinitiator, dissolving the carboxymethyl chitosan in ultrapure water, mixing, and carrying out illumination cross-linking curing. When the composite hydrogel is applied to small intestine tissue engineering, a small intestine defect part can be filled with the composite hydrogel, photo-crosslinking curing is performed to form a stent, the degradation period is matched with the small intestine regeneration period, and the antibacterial rate is gt; the cell toxicity is 0 level, a good microenvironment can be provided for cells, tissue repair can be promoted, and the compound can also be used for preparing pharmaceutical compositions for treating small intestine related diseases.

The invention provides a preparation method of a Witzia ciliaris IOB502 microbial inoculum and an application of the Witzia ciliaris IOB502 microbial inoculum in the aspect of recovering intestinal motility, the Witzia ciliaris IOB502 microbial inoculum is prepared by adopting a method of carrying out low-oxygen stress staged fermentation on chickpeas by adopting the Witzia ciliaris IOB502, and the generation of vitamins B1 and B2 can be promoted. The microbial inoculum does not affect physiological development of important organs such as liver, spleen and small intestine of mice, can improve defecation symptoms of the mice with constipation, increase defecation times and water content of excrement, improve intestinal movement of the mice with constipation, promote smooth passage of intestinal contents, effectively improve colon injury of the mice with constipation, and improve the constipation rate of the mice with constipation. Comprising mucous membrane layer thinning and mucus secretion reduction.

The invention provides a rutin-modified soybean protein isolate-pectin-genipin nano-particle carrier and a preparation method of the rutin-modified soybean protein isolate-pectin-genipin nano-particle carrier. The preparation method of the nanoparticle carrier comprises the following steps: preparing a soybean protein isolate solution, a soybean protein isolate solution after pH shift, an aqueous solution containing rutin-modified soybean protein isolate and an aqueous solution containing rutin-modified soybean protein isolate-pectin; the aqueous solution contains rutin-modified soy isolate protein-pectin-genipin, the concentration of the genipin is 0.05 mg / mL, and the rutin-modified soy isolate protein-pectin-genipin nano-particle carrier is prepared from the rutin-modified soy isolate protein-pectin-genipin nano-particle carrier. The invention further provides application of the rutin-modified soy isolate protein-pectin-genipin nanoparticle carrier. The rutin-modified soy isolate protein-pectin-genipin nanoparticle carrier is used for sustained release of gastric drugs and targeted release of drugs in small intestines. According to the preparation method disclosed by the invention, a rutin-modified soybean protein isolate-polysaccharide nanoparticle carrier with a shell-core structure can be formed, gastric acid erosion can be effectively resisted, and the rutin-modified soybean protein isolate-polysaccharide nanoparticle carrier is delivered to small intestines in a targeted manner.

The invention discloses a sugarcane polyphenol and mulberry leaf extract compound raw material and application thereof.The sugarcane polyphenol and mulberry leaf extract compound raw material comprises sugarcane polyphenol and mulberry leaf extract, the polyphenol content of the sugarcane polyphenol is larger than or equal to 20%, the DNJ content of the mulberry leaf extract is larger than or equal to 10%, and the concentration of the polyphenol and the DNJ is 0.1-2% after the sugarcane polyphenol and the mulberry leaf extract are compounded; by compounding the sugarcane polyphenol and the mulberry leaf extract, the active and passive transfer effects of glucose in small intestines are effectively blocked, so that the rate of the glucose entering blood is controlled, the blood glucose reaction after carbohydrate food is eaten is reduced, the decomposition and absorption of the intestinal tract to carbohydrates such as starch and disaccharide are delayed, the postprandial blood sugar is stabilized, and the blood sugar content is reduced. By reasonably adjusting the concentration of polyphenols and DNJ in the compound extract to be 0.1-2%, the combination of blocking and dredging can be realized, a synergistic effect is generated, more comprehensive and more stable management of blood sugar is realized, and meanwhile, natural crops are adopted, so that the product quality safety is ensured.

The invention belongs to the technical field of biological medicines, and particularly relates to a composition containing probiotics and application of the composition in regulating intestinal flora. The active polypeptide disclosed by the invention can be directly absorbed and utilized by small intestines without being digested by a human body, is high in absorption speed and high in bioavailability, and can effectively promote growth and reproduction of bifidobacterium and also promote generation of acetic acid. When the active polypeptide is independently used or combined with probiotics, the number recovery of bifidobacteria in intestinal tracts can be promoted, the growth and reproduction of enterobacter can be inhibited, and the flora balance of the intestinal tracts can be maintained.

The invention relates to the technical field of pharmaceutical preparations, and particularly provides colon-targeted pH-responsive nano-liposome and application thereof in improving oral bioavailability of saponin. Aiming at the problems of gastric acid damage, small intestine metabolism inactivation and low colon absorption efficiency during oral delivery of saponin, a three-layer core-shell structure design is adopted, wherein an inner core is composed of a saponin-phospholipid crystal compound; the middle layer is a chitosan-PEG bimolecular layer, and pH response release is realized in a colon environment with pH of 7.4; and the outer layer is modified with a folic acid-PE conjugate to enhance colon cell targeted recognition. The uniform nanoparticles with the particle size of 80 + / -5 nm are prepared by combining a gradient pH drug loading method with a microfluidic focusing technology. According to the preparation, the saponin bioavailability (AUC0-12 reaches 43.31 h. Microgram / mL) is remarkably improved, and the colon targeting property (the cell uptake rate is 52.9%) is enhanced. The innovativeness is that the gastrointestinal segmented protection and accurate colon release are synergistically realized through a multi-layer functional design, and the solubilization-permeation paradox of the traditional delivery technology is broken through.

The application provides a starch-indole acid derivative and a preparation method and application thereof, and relates to the technical field of modified starches. The starch-indole acid derivative refers to esterified starch generated by esterification reaction of starch, a condensing agent and alkali and indole acid. The starch-indole acid derivative has high resistance and can resist degradation of the stomach and small intestine. After reaching the colon site, the starch-indole acid derivative can be fermented by intestinal flora to release indole acid beneficial to intestinal health. Compared with traditional drug delivery modes such as intragastric administration and intraperitoneal injection, the starch-indole acid derivative has obvious advantages and can significantly increase the content of indole acid in the colon and hepatic portal vein blood. In addition, indole acid can activate an aromatic hydrocarbon receptor to play an immunoregulatory role. The immunoregulatory role of indole acid is superimposed on the regulation role of short-chain fatty acids released by starch fermentation by intestinal flora, so that a product playing an immunoregulatory role through multiple immune system signal pathways is provided.

The invention relates to a nanoparticle system for small intestine delivery, which is used for delivering exogenous miR-122-5p to the intestinal tract and comprises a miRNA-protamine compound inner core, a liposome middle layer wrapping the inner core and a p123 functional shell wrapping the liposome. Due to the adoption of the technical scheme, a nano-targeting delivery technology is combined with paternal epigenetic programming intervention for the first time, and a brand-new nano-drug treatment thought is provided for intergenerational genetic diseases caused by exposure of environmental adverse factors. By delivering exogenous miR-122-5p to the intestinal tract, the miRNA spectrum unbalanced due to exposure of paternal BaP can be directly improved.

The invention relates to the technical field of organ transplantation, and discloses organ preserving fluid, application and organ dynamic supercooling perfusion equipment. The organ preserving fluid is prepared from ribose, glucose, mannitol, lidocaine, adenosine, a high-molecular polymer, L-proline, trehalose, inorganic salt and organic salt. The high-molecular polymer comprises one of hydroxyethyl starch, polyethylene glycol and albumin. According to the organ preserving fluid disclosed by the invention, the freezing point of the perfusate is reduced through the micromolecular cryoprotectant, and meanwhile, the micromolecular cryoprotectant and the high-molecular polymer jointly inhibit formation and growth of ice crystals; the problem of liquid preservation at the temperature below zero is solved from the two dimensions of physics (reducing the freezing point and inhibiting ice crystals) and biology (maintaining cell viability), and feasibility is provided for long-time low-temperature transfer and transplantation of organs. The preserving fluid can be used for static preservation or perfusion preservation of various organs such as kidney, liver, heart, pancreas, lung, small intestine, skin and the like.

The invention relates to the technical field of image processing, in particular to a small intestine capsule endoscope target detection method which comprises the following steps: acquiring a small intestine capsule endoscope image; the method comprises the following steps: constructing an improved RT-DETR network, inserting an SCSA module between a backbone network and a neck network of the RT-DETR, and introducing a DFM module behind a three-branch Fusion module of the neck network; and the improved RT-DETR network adopts a Focaler-IoU loss function. According to the method, the problem that the accuracy of recognizing the tumor target by using the small intestine capsule endoscope image through RT-DETR needs to be further improved is solved.

The invention provides a briracetam sustained-release pharmaceutical composition as well as a preparation method and application thereof. The pharmaceutical composition comprises a pharmaceutical active ingredient and a pharmaceutical excipient, wherein the pharmaceutical excipient is selected from one or more of a framework material, a disintegrating agent, a swelling agent, an adhesive, a filler and a lubricant. The briracetam sustained-release pharmaceutical composition disclosed by the invention is good in sustained-release effect, stable in release speed and small in side effect, the medicine taking frequency is reduced, and the compliance of a patient is improved; the retention time of the medicine in the stomach is prolonged, so that the medicine is continuously released in the stomach and is absorbed at the upper end of the small intestine, the effect of continuously taking effect for 24 hours is achieved, the plasma concentration is stable, and the adverse reaction is small; a patient is prevented from randomly interrupting medication, and disease relapse and malignant complication development are prevented; the medicine is few in administration times, convenient to take and small in toxic and side effects.

The invention discloses an implantable acellular matrix material and a preparation method thereof, and belongs to the field of biomedical materials. According to the method, natural animal tissues (such as pericardium, achilles tendon or small intestine submucosa) are used as raw materials, a low-temperature chemical combined decellularization treatment technology is adopted, and the method comprises the multi-step synergistic process of pre-cooling soaking balancing, low-temperature enzymolysis, low-concentration surfactant gradient permeation cleaning, low-temperature nuclease degradation, non-crosslinking sterilization and the like. Under the condition that the treatment temperature is strictly kept at 0-8 DEG C, cell components and genetic materials (the residual DNA content is 1t, and the dry weight is 8 ng / mg) are efficiently removed, and meanwhile the natural three-dimensional fine structure of an extracellular matrix (ECM), the integrity of collagen fibrils and key bioactive components (such as glycosaminoglycans (GAGs)) are reserved to the maximum extent. The host immunological rejection reaction of the obtained material is remarkably reduced, host cell ingrowth, vascularization and tissue function reconstruction can be effectively promoted after implantation, and the material is suitable for high-end implantation scenes such as soft tissue repair and regenerative medical stents.

The present invention discloses a method for inhibiting the digestion of lactoferrin in the human body. By preparing a complex of caffeine and lactoferrin and simulating in vitro digestion tests, it is found that caffeine increases the retention rate of lactoferrin in the oral cavity and intestine, while decreasing the retention rate in the stomach. This is beneficial for lactoferrin to bind with free oxygen radicals proximal to the pylorus of the small intestine, helping to protect the body from their harmful effects. The present invention prepares a complex of caffeine and lactoferrin, which can inhibit the digestion of lactoferrin in the human body, plays a positive role in enabling lactoferrin to better exert its functional characteristics, and at the same time, highly nutritious lactoferrin has broad application prospects in the development of functional foods.

The present invention provides, in part, compositions comprising a peptide that is larazotide or larazotide derivative, or salt thereof, contained within a matrix that provides for controlled release and sustained release formulations. The present invention contemplates that these compositions, formulations and methods can be useful for treating diseases and disorders of the small bowel.

The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder, and belongs to the technical field of compound amoxicillin, and the method comprises the following steps: (1) simulating a gastric acid environment, and respectively adding different compound amoxicillin powder samples to obtain different sample solutions; (2) simulating a small intestine environment for different sample solutions obtained in the step (1); and (3) sampling different sample solutions after the step (2), measuring the minimum inhibitory concentration, and comparing the effect of the compound amoxicillin powder sample to evaluate. The invention provides a method for evaluating the minimum inhibitory concentration of compound amoxicillin powder. The method is simple to operate and can quickly and accurately evaluate the effect of the compound amoxicillin powder.

The utility model provides a multi-point small intestine sampling device, and belongs to the technical field of medical instruments. The multi-point small intestine sampling device comprises a small intestine sampling tube which is provided with a guide wire channel, a balloon connecting channel and a plurality of sampling channels, and the side wall of the small intestine sampling tube is provided with suction ports communicated to the corresponding sampling channels at different preset positions; the balloon is arranged at one end of the small intestine sampling tube, and the balloon is respectively communicated with the guide wire channel and the balloon connecting channel; and a gravity hammer. The multi-point small intestine sampling device disclosed by the utility model can reach a specified position along with peristalsis to sample a specific area. Moreover, the balloon is respectively communicated with the guide wire channel and the balloon connecting channel, so that the utilization efficiency of an internal channel of the small intestine sampling tube is improved, the radial cross section of the balloon connecting channel is reduced, the radial outer diameter of the small intestine sampling tube can be as small as possible, and the discomfort of a patient is reduced when the small intestine sampling tube is introduced into the intestinal tract of the patient.

The invention belongs to the technical field of vitamin coating and animal breeding, and particularly relates to coated 25-hydroxyvitamin D3, a preparation method thereof and application of the coated 25-hydroxyvitamin D3 in improving the lactation performance and milk quality of ruminants. The 25-hydroxyvitamin D3 disclosed by the invention can regulate and control the release rate of the 25-hydroxyvitamin D3 in rumen and small intestines, so that the 25-hydroxyvitamin D3 can reach the small intestines to be absorbed to the greatest extent, the nutrition regulation and control function of the 25-hydroxyvitamin D3 is fully played, the lactation performance of dairy cows is improved, meanwhile, the lipid metabolism of ruminants can be regulated and controlled, and the lactose content in milk can be increased. The test result shows that by adding the coated 25-hydroxyvitamin D3 into the basic ration of the dairy cow, the milk yield of the dairy cow can be increased, and meanwhile, the fat content and the lactose content in the milk can be remarkably increased. Therefore, the coated 25-hydroxyvitamin D3 can improve the feed efficiency, reduce the feeding cost and improve the production benefit.